Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

医学 溃疡性结肠炎 维持疗法 诱导疗法 内科学 结肠炎 化疗 疾病
作者
Geert D’Haens,Marla Cindy Dubinsky,Taku Kobayashi,Peter Miles Irving,Stefanie M. Howaldt,Juris Pokrotnieks,Kathryn A. Krueger,Janelle Laskowski,Xingyuan Li,Trevor W. Lissoos,Joe Milata,Nathan J. Morris,Vipin Arora,Catherine E. Milch,William J. Sandborn,Bruce E. Sands
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:388 (26): 2444-2455 被引量:377
标识
DOI:10.1056/nejmoa2207940
摘要

BACKGROUND: Mirikizumab, a p19-directed antibody against interleukin-23, showed efficacy in the treatment of ulcerative colitis in a phase 2 trial. METHODS: We conducted two phase 3, randomized, double-blind, placebo-controlled trials of mirikizumab in adults with moderately to severely active ulcerative colitis. In the induction trial, patients were randomly assigned in a 3:1 ratio to receive mirikizumab (300 mg) or placebo, administered intravenously, every 4 weeks for 12 weeks. In the maintenance trial, patients with a response to mirikizumab induction therapy were randomly assigned in a 2:1 ratio to receive mirikizumab (200 mg) or placebo, administered subcutaneously, every 4 weeks for 40 weeks. The primary end points were clinical remission at week 12 in the induction trial and at week 40 (at 52 weeks overall) in the maintenance trial. Major secondary end points included clinical response, endoscopic remission, and improvement in bowel-movement urgency. Patients who did not have a response in the induction trial were allowed to receive open-label mirikizumab during the first 12 weeks of the maintenance trial as extended induction. Safety was also assessed. RESULTS: A total of 1281 patients underwent randomization in the induction trial, and 544 patients with a response to mirikizumab underwent randomization again in the maintenance trial. Significantly higher percentages of patients in the mirikizumab group than in the placebo group had clinical remission at week 12 of the induction trial (24.2% vs. 13.3%, P<0.001) and at week 40 of the maintenance trial (49.9% vs. 25.1%, P<0.001). The criteria for all the major secondary end points were met in both trials. Adverse events of nasopharyngitis and arthralgia were reported more frequently with mirikizumab than with placebo. Among the 1217 patients treated with mirikizumab during the controlled and uncontrolled periods (including the open-label extension and maintenance periods) in the two trials, 15 had an opportunistic infection (including 6 with herpes zoster infection) and 8 had cancer (including 3 with colorectal cancer). Among the patients who received placebo in the induction trial, 1 had herpes zoster infection and none had cancer. CONCLUSIONS: Mirikizumab was more effective than placebo in inducing and maintaining clinical remission in patients with moderately to severely active ulcerative colitis. Opportunistic infection or cancer occurred in a small number of patients treated with mirikizumab. (Funded by Eli Lilly; LUCENT-1 and LUCENT-2 ClinicalTrials.gov numbers, NCT03518086 and NCT03524092, respectively.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
失眠世立完成签到 ,获得积分10
1秒前
李寳完成签到,获得积分10
1秒前
xxw完成签到,获得积分10
1秒前
电解质完成签到,获得积分10
1秒前
千流完成签到,获得积分10
1秒前
研友_Ljqal8发布了新的文献求助10
2秒前
help完成签到,获得积分10
2秒前
hus完成签到,获得积分10
2秒前
tyro完成签到,获得积分10
2秒前
蓬莱依月完成签到,获得积分10
2秒前
husky完成签到,获得积分10
3秒前
马俊完成签到,获得积分10
3秒前
HZN完成签到,获得积分10
3秒前
4秒前
Harrisonhuang完成签到,获得积分10
4秒前
GGbond完成签到,获得积分10
4秒前
啊哈完成签到,获得积分10
4秒前
超帅发夹完成签到 ,获得积分10
4秒前
白敬亭发布了新的文献求助10
5秒前
guan完成签到,获得积分10
5秒前
Ywwww完成签到 ,获得积分10
6秒前
小太阳完成签到,获得积分10
7秒前
7秒前
天真的完成签到,获得积分10
7秒前
jiaxiangyu完成签到,获得积分10
7秒前
夜瞳完成签到,获得积分10
7秒前
Polly完成签到,获得积分10
8秒前
马麻薯完成签到,获得积分10
8秒前
林慕然2023完成签到,获得积分10
8秒前
深井的朵拉完成签到,获得积分10
9秒前
研友_VZG7GZ的应助被杨媛采纳,获得10
9秒前
9秒前
33完成签到 ,获得积分10
9秒前
9秒前
luyue9406的应助被MINI采纳,获得20
10秒前
bulanshitake完成签到,获得积分10
10秒前
10秒前
姚波完成签到,获得积分10
10秒前
卡佳完成签到,获得积分10
10秒前
笔不尖完成签到 ,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039